All Updates

All Updates

icon
Filter
Partnerships
AmoyDx partners with Servier to provide companion diagnostic solutions for diffuse glioma in China
Precision Medicine
Jun 26, 2024
This week:
Partnerships
Sheeva.AI and P97 Networks partner for in-car payment solutions at fuel stations
Auto Tech
Today
Product updates
Food Cycle Science launches 'Food Cycler Eco 3,' a household food waste processing bin
Food Waste
Yesterday
Partnerships
Von Holzhausen and Herman Miller partner to launch plant-based leather Eames Chair
Bio-based Materials
Yesterday
Partnerships
Volvo Cars partners with Beijing Shougang and Zhejiang Yiyun for automotive steel recycling
Waste Recovery & Management Tech
Yesterday
Funding
LanzaJet receives strategic investment from Airbus
Carbon Capture, Utilization & Storage (CCUS)
Yesterday
Funding
LanzaJet receives strategic investment from Airbus
Alternative Energy
Yesterday
Partnerships
Odie Pet Insurance partners with Insuritas to offer pet coverage through financial institutions
Pet Care Tech
Yesterday
Partnerships
Odie Pet Insurance partners with Insuritas to offer pet coverage through financial institutions
InsurTech: Personal Lines
Yesterday
M&A
Applied Systems acquires Planck for undisclosed sum to expand AI capabilities
InsurTech: Infrastructure
Yesterday
Product updates
Monzo launches pension consolidation product
Neobanks
Yesterday
Precision Medicine

Precision Medicine

Jun 26, 2024

AmoyDx partners with Servier to provide companion diagnostic solutions for diffuse glioma in China

Partnerships

  • Amoy Diagnostics (AmoyDx) has entered a strategic partnership with Servier to co-develop a companion diagnostic (CDx) test for detecting isocitrate dehydrogenase (IDH) 1 and 2 gene mutations.

  • ​​The partnership aims to develop a diagnostic tool for identifying IDH gene mutations, which will be used in the research for a novel drug, "vorasidenib." This drug is designed to inhibit these mutations and is expected to be used to treat Diffuse Lower Grade Glioma patients who carry these mutations in China. AmoyDx will use its Next-Generation Sequencing (NGS) technology for this development and support the drug's registration and commercialization in mainland China. 

  • China-based Amoy Diagnostics specializes in molecular diagnostics for oncology precision medicine. The company offers a range of diagnostic products, including PCR, NGS, FISH, and IHC assays, under proprietary brands such as ADx-ARMS, Super-ARMS, and ADx-HANDLE. AmoyDx also operates the Xiamen Amoy Medical Laboratory and the Shanghai Xiawei Medical Laboratory, which provide third-party clinical inspection services.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.